As of 2025-01-25, the Relative Valuation of Blueprint Medicines Corp (BPMC) is (37.29) USD. This relative valuation is based on P/E multiples. With the latest stock price at 114.91 USD, the upside of Blueprint Medicines Corp based on Relative Valuation is -132.4%.
The range of the Relative Valuation is (36.48) - (40.35) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.4x - 31.6x | 18.1x |
| Forward P/E multiples | 18.1x - 20.0x | 18.9x |
| Fair Price | (36.48) - (40.35) | (37.29) |
| Upside | -131.7% - -135.1% | -132.4% |
| Date | P/E |
| 2025-01-23 | -57.37 |
| 2025-01-22 | -55.11 |
| 2025-01-21 | -55.55 |
| 2025-01-17 | -54.60 |
| 2025-01-16 | -51.57 |
| 2025-01-15 | -52.04 |
| 2025-01-14 | -50.88 |
| 2025-01-13 | -51.28 |
| 2025-01-10 | -43.38 |
| 2025-01-08 | -44.96 |
| 2025-01-07 | -46.82 |
| 2025-01-06 | -44.42 |
| 2025-01-03 | -43.83 |
| 2025-01-02 | -43.26 |
| 2024-12-31 | -43.27 |
| 2024-12-30 | -43.07 |
| 2024-12-27 | -44.35 |
| 2024-12-26 | -45.46 |
| 2024-12-24 | -44.88 |
| 2024-12-23 | -44.82 |
| 2024-12-20 | -44.72 |
| 2024-12-19 | -44.12 |
| 2024-12-18 | -45.54 |
| 2024-12-17 | -47.87 |
| 2024-12-16 | -47.33 |
| 2024-12-13 | -46.23 |
| 2024-12-12 | -45.93 |
| 2024-12-11 | -46.87 |
| 2024-12-10 | -47.33 |
| 2024-12-09 | -46.92 |
| 2024-12-06 | -47.61 |
| 2024-12-05 | -47.17 |
| 2024-12-04 | -47.89 |
| 2024-12-03 | -47.89 |
| 2024-12-02 | -48.43 |
| 2024-11-29 | -47.82 |
| 2024-11-27 | -47.18 |
| 2024-11-26 | -46.95 |
| 2024-11-25 | -46.57 |
| 2024-11-22 | -46.71 |
| 2024-11-21 | -47.94 |
| 2024-11-20 | -47.04 |
| 2024-11-19 | -46.93 |
| 2024-11-18 | -44.74 |
| 2024-11-15 | -44.00 |
| 2024-11-14 | -47.46 |
| 2024-11-13 | -48.07 |
| 2024-11-12 | -47.94 |
| 2024-11-11 | -49.55 |
| 2024-11-08 | -50.03 |